{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelioma%3B+Liver&page=2", "query": { "condition": "Mesothelioma; Liver", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mesothelioma%3B+Liver&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T01:36:26.209Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03517488", "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma" ], "interventions": [ { "name": "XmAb20717", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2018-07-10", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 17, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517488" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2017-04-25", "completion_date": "2021-11-09", "has_results": true, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 15, "location_summary": "Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126110" }, { "nct_id": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Hepatocellular Cancer", "Mesothelioma", "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Nasopharyngeal Cancer", "Kidney Cancer", "Squamous Cell Cancer of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC), Non-squamous" ], "interventions": [ { "name": "TAK-500", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-04-14", "completion_date": "2025-01-06", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070247" }, { "nct_id": "NCT05199584", "title": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors With PTCH1 Loss-of-function Mutations" ], "interventions": [ { "name": "ENV-101 (taladegib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endeavor Biomedicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-05-24", "completion_date": "2024-02-20", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199584" }, { "nct_id": "NCT00375245", "title": "Rapamycin With Grapefruit Juice for Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Neoplasm Metastasis" ], "interventions": [ { "name": "Rapamycin (sirolimus)", "type": "DRUG" }, { "name": "Grapefruit Juice", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-09", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2014-01-17", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00375245" }, { "nct_id": "NCT05732831", "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor" ], "interventions": [ { "name": "TNG462", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tango Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2023-05-26", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 15, "location_summary": "Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05732831" }, { "nct_id": "NCT04214015", "title": "A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Mesothelioma", "Mesothelioma Malignant", "Mesothelioma; Lung", "Mesotheliomas Pleural", "Mesothelioma Peritoneum", "Mesothelioma; Liver", "Mesothelioma; Omentum" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2020-03-02", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2025-06-05", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214015" }, { "nct_id": "NCT00066404", "title": "Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "recombinant adenovirus-hIFN-beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-04", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066404" }, { "nct_id": "NCT04792463", "title": "Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Uveal Melanoma", "Cutaneous Melanoma", "BAP1 Gene Mutation", "Renal Cell Carcinoma", "Mesothelioma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Meningioma Atypical" ], "interventions": [], "intervention_types": [], "sponsor": "Mohamed Abdel-Rahman", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 500, "start_date": "2015-03-03", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-07-24T01:36:26.209Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04792463" } ] }